Coverage dated October 23, 2026

STAT+: Tango builds on Revolution Medicines’ pancreatic cancer success

Headline from STAT

As the ESMO conference kicks off, Tango's pancreatic cancer combination shows striking promise and detailed data on Moderna and Merck's cancer vaccine is released early.

STAT's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

3 articles, oldest first.

STAT
STAT+: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer (opens STAT)
Published Oct 23, 2026
STAT's feed description
An experimental drug combination led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, Tango Therapeutics reported.
Investor's Business Daily
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug (opens Investor's Business Daily)
Published Oct 23, 2026
Investor's Business Daily's feed description
Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic cancer.
STAT
STAT+: Tango builds on Revolution Medicines’ pancreatic cancer success (opens STAT)
Published Oct 23, 2026
STAT's feed description
As the ESMO conference kicks off, Tango's pancreatic cancer combination shows striking promise and detailed data on Moderna and Merck's cancer vaccine is released early.